**Supplementary Table S3.** Demographics and clinical characteristics of 93 ADC patients according to PD-L1 expression.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristic** | | | **PD-L1** | | | **P** |
| **Strong**  **(≥50%)** | **Weak**  **(5-49%)** | **Negative**  **(<5%)** |
| **No. of patients** | 93 | | 19 (20.4) | 27 (29.1) | 47 (50.5) |  |
| **Age** |  | |  |  |  |  |
| **Mean, yrs** | 61.0 | | 60.0 | 60.0 | 62.0 |  |
| **Range** | 29 – 82 | | 45 – 74 | 41 – 77 | 29 – 82 |  |
| **Gender** | |  | |  |  |  |
| **Male** | 53 | | 12 (22.6) | 16 (30.2) | 25 (47.2) | 0.730 |
| **Female** | 40 | | 7 (17.5) | 11 (27.5) | 22 (55.0) |  |
| **Smoking** |  | |  |  |  |  |
| **Never** | 58 | | 12 (20.7) | 16 (27.6) | 30 (51.7) | 0.924 |
| **Ever** | 35 | | 7 (20.0) | 11 (31.4) | 17 (48.6) |  |
| **Stage** |  | |  |  |  |  |
| **I** | 50 | | 6 (12.0) | 17 (34.0) | 27 (54.0) | 0.131 |
| **II** | 16 | | 3 (18.8) | 4 (25.0) | 9 (56.2) |  |
| **III** | 27 | | 10 (37.0) | 6 (22.3) | 11 (40.7) |  |
| **EGFR** | |  | |  |  |  |
| **Mutation** | 45 | | 5 (11.4) | 16 (36.4) | 23 (52.3) | 0.084 |
| **Wild type** | 48 | | 14 (28.6) | 11 (22.4) | 24 (49.0) |  |
| **KRAS** | |  | |  |  |  |
| **Mutation** | 10 | | 3 (30.0) | 4 (40.0) | 3 (30.0) | 0.386 |
| **Wild type** | 83 | | 16 (19.3) | 23 (27.7) | 44 (53.0) |  |
| **TP53** | |  | |  |  |  |
| **Mutation** | 38 | | 13 (34.2) | 9 (23.7) | 16 (42.1) | **0.023** |
| **Wild type** | 55 | | 6 (10.9) | 18 (32.7) | 31 (56.4) |  |

Abbreviations: ADC, adenocarcinoma; PD-L1, Programmed death-ligand 1; EGFR, epidermal growth factor receptor.